Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P00325

UPID:
ADH1B_HUMAN

ALTERNATIVE NAMES:
Alcohol dehydrogenase 1B; Alcohol dehydrogenase subunit beta

ALTERNATIVE UPACC:
P00325; A8MYN5; B4DRS9; B4DVC3; Q13711; Q4ZGI9; Q96KI7

BACKGROUND:
The enzyme All-trans-retinol dehydrogenase [NAD(+)] ADH1B, alternatively known as Alcohol dehydrogenase 1B, is integral to the metabolism of retinoids, catalyzing the NAD-dependent oxidation and NADH-dependent reduction of all-trans-retinol and its derivatives. This enzyme's activity is crucial for maintaining the balance of retinoids, essential components in vision, growth, and cellular differentiation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of All-trans-retinol dehydrogenase [NAD(+)] ADH1B unveils potential pathways for therapeutic interventions. Given its central role in retinoid metabolism, targeting this enzyme could lead to innovative treatments for diseases linked to retinoid imbalance, highlighting the importance of further research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.